Katharina Schultebraucks1, Katja Wingenfeld2, Jana Heimes3, Marcus Quinkler4, Christian Otte2. 1. Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Berlin, Germany. Electronic address: Katharina.Schultebraucks@charite.de. 2. Department of Psychiatry and Psychotherapy, Charité University Medical Center, Campus Benjamin Franklin, Berlin, Germany. 3. Department of Psychology, Humboldt-University, Berlin, Germany. 4. Clinical Endocrinology, Charité University Medical Center, Campus Mitte, Berlin, Germany; Endocrinology in Charlottenburg, Berlin, Germany.
Abstract
BACKGROUND: Patients with primary adrenal insufficiency (AI) need to replace glucocorticoids and mineralocorticoids that act on glucocorticoid (GR) and mineralocorticoid receptors (MR). Both receptors are highly expressed in the hippocampus and are closely associated with cognitive function, which might be impaired by insufficient or increased GR and MR stimulation. However, little is known about cognitive function in patients with AI. METHODS: It was examined whether patients with AI exhibit worse cognitive function compared to sex-, age-, and education-matched controls. Cognitive function (executive function, concentration, verbal memory, visual memory, working memory, and autobiographical memory) was assessed in 30 patients with AI (mean age 52.4 yrs. ±14.4, n=21 women, mean duration of illness 18.2 yrs. ±11.1) and 30 matched controls. We also measured depressive symptoms, body mass index (BMI), and blood pressure. RESULTS: Patients with AI showed more depressive symptoms, had a greater BMI and lower systolic blood pressure compared to controls. Adjusted analyses controlling for these variables revealed that patients with AI performed significantly worse in verbal learning (F=7.8, p=.007). Executive function, concentration, working memory, verbal memory, visuospatial memory, and autobiographical memory did not differ between groups. CONCLUSIONS: No clinically relevant cognitive impairment was found in patients with AI compared to matched controls. Even long-term glucocorticoid and mineralocorticoid substitution over almost two decades appears to have only subtle effects on cognition in patients with AI.
BACKGROUND:Patients with primary adrenal insufficiency (AI) need to replace glucocorticoids and mineralocorticoids that act on glucocorticoid (GR) and mineralocorticoid receptors (MR). Both receptors are highly expressed in the hippocampus and are closely associated with cognitive function, which might be impaired by insufficient or increased GR and MR stimulation. However, little is known about cognitive function in patients with AI. METHODS: It was examined whether patients with AI exhibit worse cognitive function compared to sex-, age-, and education-matched controls. Cognitive function (executive function, concentration, verbal memory, visual memory, working memory, and autobiographical memory) was assessed in 30 patients with AI (mean age 52.4 yrs. ±14.4, n=21 women, mean duration of illness 18.2 yrs. ±11.1) and 30 matched controls. We also measured depressive symptoms, body mass index (BMI), and blood pressure. RESULTS:Patients with AI showed more depressive symptoms, had a greater BMI and lower systolic blood pressure compared to controls. Adjusted analyses controlling for these variables revealed that patients with AI performed significantly worse in verbal learning (F=7.8, p=.007). Executive function, concentration, working memory, verbal memory, visuospatial memory, and autobiographical memory did not differ between groups. CONCLUSIONS: No clinically relevant cognitive impairment was found in patients with AI compared to matched controls. Even long-term glucocorticoid and mineralocorticoid substitution over almost two decades appears to have only subtle effects on cognition in patients with AI.
Authors: Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: J Natl Cancer Inst Date: 2018-04-01 Impact factor: 13.506
Authors: Yin Ting Cheung; Wassim Chemaitilly; Daniel A Mulrooney; Tara M Brinkman; Wei Liu; Pia Banerjee; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Psychoneuroendocrinology Date: 2016-11-16 Impact factor: 4.905
Authors: William R Lovallo; Mary-Anne Enoch; Ashley Acheson; Andrew J Cohoon; Kristen H Sorocco; Colin A Hodgkinson; Andrea S Vincent; David Goldman Journal: Neuropsychopharmacology Date: 2015-12-03 Impact factor: 7.853
Authors: Antje K Blacha; Peter Kropp; Amir H Rahvar; Jörg Flitsch; Iris van de Loo; Birgit Harbeck Journal: Ir J Med Sci Date: 2021-08-13 Impact factor: 2.089